- SEK27.86bn
- SEK25.86bn
- SEK2.00bn
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million
Brief: BioArctic: Leqembi To Generate About SEK 880 Million In Royalty
Sweden's BioArctic Q4 revenue rises 82% on Leqembi royalties
Brief: Bioarctic Proposes Dividend Of 2.00 Sek Per Share For 2025
Brief: BioArctic Reports Q4 Sales Of Leqembi At SEK 20.7 Billion
Brief: Eisai submits Marketing Authorisation Variation to EMA
Brief: Eisai Submits Marketing Authorisation Variation To EMA For Intravenous Maintenance Dosing With Leqembi
Brief: BioArctic Says FDA Grants Priority Review To Leqembi Iqlik Supplemental Application
Brief: Leqembi Included In China's Commercial Insurance Innovative Drug List
Brief: Bioarctic Says Leqembi-Data Suggests Potential To Delay Disease Progression
Brief: BioArctic Says New Drug Application For Subcutaneous Formulation Of Leqembi Submitted In Japan
Brief: Bioarctic Says Leqembi Approved For IV Maintenance Treatment In United Kingdom
Brief: BioArctic Q3 Operating Profit SEK -28.8 Million
Brief: Bioarctic AB Says Health Canada Grants Authorization For Leqembi® (Lecanemab)
Brief: Bioarctic Leqembi® Approved For Iv Maintenance Treatment In China
Brief: BioArctic's Leqembi Approved For Treatment Of Early Alzheimer's Disease In Australia